Split History
RARE split history picture
Ultragenyx Pharmaceutical (RARE) has 2 splits in our RARE split history database. The first split for RARE took place on September 06, 2000. This was a 3 for 2 split, meaning for each 2 shares of RARE owned pre-split, the shareholder now owned 3 shares. For example, a 1000 share position pre-split, became a 1500 share position following the split. RARE's second split took place on September 03, 2003. This was a 3 for 2 split, meaning for each 2 shares of RARE owned pre-split, the shareholder now owned 3 shares. For example, a 1500 share position pre-split, became a 2250 share position following the split.

When a company such as Ultragenyx Pharmaceutical splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business.

Looking at the RARE split history from start to finish, an original position size of 1000 shares would have turned into 2250 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Ultragenyx Pharmaceutical shares, starting with a $10,000 purchase of RARE, presented on a split-history-adjusted basis factoring in the complete RARE split history. RARE split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 11/21/2014
End date: 12/08/2022
Start price/share: $44.09
End price/share: $41.21
Dividends collected/share: $0.00
Total return: -6.53%
Average Annual Total Return: -0.84%
Starting investment: $10,000.00
Ending investment: $9,343.32
Years: 8.05
Ultragenyx Pharmaceutical is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Co. has four commercially approved products, Crysvita® (burosumab) for the treatment of X-linked hypophosphatemia and tumor-induced osteomalacia, Mepsevii® (vestronidase alfa) for the treatment of mucopolysaccharidosis VII, or Sly Syndrome, Dojolvi® (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders, and Evkeeza® (evinacumab) for the treatment of homozygous familial hypercholesterolemia. According to our RARE split history records, Ultragenyx Pharmaceutical has had 2 splits.
Date Ratio
09/06/20003 for 2
09/03/20033 for 2
RARE is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

RCKT Split History
RCPI Split History
RDNT Split History
RDY Split History
REPH Split History
RGLS Split History
RHE Split History
RMD Split History
RMTI Split History
RNN Split History

Also explore: RARE shares outstanding history

Email EnvelopeFree RARE Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Checkpoint Therapeutics, Inc. (CKPT)
UpHealth, Inc. (UPH)
MediWound Ltd. (MDWD)
Eloxx Pharmaceuticals, Inc. (ELOX)
Baudax Bio, Inc. (BXRX)
Petros Pharmaceuticals, Inc. (PTPI)
Tuesday Morning Corporation (TUEM)
DURECT Corporation (DRRX)
CNS Pharmaceuticals, Inc. (CNSP)
Astrotech Corporation (ASTC)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

RARE Insider Buying

RARE Split History | www.SplitHistory.com | Copyright © 2013 - 2022, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.